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Abstract
Background: Eosinophilic gastrointestinal disorders are an emerging disease entity characterized
by eosinophilic infiltration of the intestinal wall. Oral steroids can be still considered as first line
treatment. Unfortunately relapses are quite common. Usually long term low-dose prednisone or
immunosuppressive therapy is required, which is especially problematic in young patients. Thus a
reliable steroid sparing agent with low side effects suitable for long term use is needed. There are
strong hints to a similar pathophysiology of eosinophilic gastrointestinal disorders to that of
asthma. Indeed leukotriene D4 plays an important role in the recruitment of eosinophils into the
intestinal tissue causing damage. This patho-mechanism provides the rationale for the treatment
with a leukotriene D4 receptor antagonist. Recently there have been first reports about successful
short term use of Montelukast in eosinophilic gastrointestinal disorders.
Case presentation: We report the case of a 17 year old girl with a long history of severe
abdominal complaints leading to several hospitalizations in the past. Mimicking the picture of an
intestinal tuberculosis she received an anti mycobacterial treatment without any success. Marked
eosinophilia in blood, ascites and tissue samples of the intestinal tract finally lead to the diagnosis
eosinophilic gastroenteritis. Tapering off prednisone caused another severe episode of abdominal
pain. At that point leukotriene antagonist Montelukast was started at a dose of 10 mg once daily.
Steroids could be tapered off completely within six weeks. The patient has been free of symptoms
for over two years by now. Routine examinations, blood tests and endoscopy have rendered
regular results. So far no side effects were noted.
Conclusion: Here report about successful long term remission of eosinophilic gastroenteritis
under Montelukast. Further randomized control trials are required to asses the full benefits of
Montelukast therapy in the whole spectrum of eosinophilic gastrointestinal disorders.
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Eosinophilic gastroenteritis is a rare disease characterized
by eosinophilic infiltration of the intestinal wall. It may
mimic peptic ulcer, intestinal obstruction, gastroenteritis,
irritable bowel syndrome, and inflammatory bowel dis-
ease. Long-term personal history of digestive symptoms
and the course of the disease with relapses and remissions
is the key for the disease to be suspected. Endoscopy, CT
scan and sonographic studies may provide important
indirect signs of the disease. But only in combination with
histological examination the diagnosis can be achieved.
Primary eosinophilic gastrointestinal disorders (EGID)
selectively affect the gastrointestinal tract with eosinophil
rich inflammation in the absence of known causes for
eosinophilia[1]. The natural history of EGIDs has not
been well documented, however these diseases are often
chronic waxing and waning disorders. The clinical presen-
tation depends on the gastrointestinal division affected
and the wall layers infiltrated.
EGIDs are primarily polygenic allergic disorders involving
mechanisms that fall between IgE-mediated food allergy
and cellular-mediated hypersensitivity disorders[1]. Ster-
oids are still the main therapy for cases in which diet
restriction is not feasible or has failed. The recent research
suggests a similar pathophysiology to asthma[2]. Cystei-
nyl leukotrienes have potent chemo attractant properties
for eosinophils. Together with interleukin 3 and 5 they
play a major role in the recruitment of eosinophils into
the tissue causing damage[3]. Disrupting this vicious cir-
cle may provide the rationale for treating patients with
eosinophilic gastroenteritis with leukotriene receptor
antagonists (LTRA).
Here we report a case of young women with a long history
of eosinophilic gastroenteritis. Under therapy with the
LTRA Montelukast she has been completely free of symp-
toms for over two years by now. Routine physical exami-
nations and blood tests have rendered regular results.
Case report
A 17-year-old girl was admitted to the local gynaecology
unit with recurrent abdominal cramps, nausea and vomit-
ing. She had a history of repeated episodes of abdominal
pain in the past. The symptoms had begun some years ear-
lier, causing several hospitalizations and two laparoscopic
interventions.
Medical history revealed allergic coryza and neuroderma-
titis, but no food allergy. No other diseases were reported.
Laboratory rendered a high white blood cell count (WBC)
13.300 × 109/liter with an eosinophil count of 58% and
CRP 5.2 mg/l. Laparoscopy showed a large amount of
ascites and swollen intraabdominal lymph nodes. Thus,
screening for tuberculosis was initiated. A chest x-ray
showed no signs of pulmonary disease, Mantoux test and
all cultures remained negative. However, one pcr from
ascites was positive and the diagnosis of intestinal tuber-
culosis was established. The patient was started on
rifampicin, isoniazid, ethambutol and pyrazinamide.
Despite treatment symptoms persisted for the following
six month.
On admission the patient was still under therapy with
rifampicin and isoniazid. Physical examination demon-
strated diffuse abdominal tenderness without peritoneal
signs. The WBC was 13100 × 109/liter with an eosi-
nophilic count of 53 %, total IgE 1870 kU/l and CRP 32
mg/l. Clinical and laboratory indices for autoimmune dis-
ease were absent. Abdominal ultrasound and computed
tomography showed ubiquitous ascites and thickening of
the wall of the lower oesophagus, stomach and bowel
(Fig. 1). The patient developed severe abdominal pain,
only controlled by opoid analgesia. An iliac crest biopsy
showed an eosinophilic count over 40 percent but no
signs of leukaemia. Again the ascitic fluid rendered a high
eosinophilic count. Blood tests as well as stool cultures
and microscopy for ova and parasites were negative.
Endoscopy of the upper intestinum and the colon showed
no abnormalities of the intestinal mucosa. Remarkably
biopsies from oesophagus, stomach, ileum and colon
Contrast-enhanced spiral CT revealing ascites and concentric thickening of colon and i eumFigu e 1
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lamina propria which finally lead to the diagnosis of a pri-
mary eosinophilic gastrointestinal disorder (Fig. 2).
Thus, this patient fulfilled all diagnostic criteria for eosi-
nophilic gastroenteritis. Since active tuberculosis was
ruled out we stopped anti-mycobacterial treatment.
The patient was switched to 40 mg prednisone per day.
Symptoms were alleviated quickly in the beginning. The
patient was set on a taper. Reaching a dose of 10 mg a day
symptoms started again. Therefore the dose was doubled
and Montelukast 10 mg/d was started. The symptoms
resolved within days and the prednisone could be tapered
within six weeks. Currently, the patient remains com-
pletely off steroids. She has been symptom free for the last
24 months under Montelukast. Regular physical examina-
tions and blood tests have shown normal results.
Discussion
EGIDs are primarily polygenic allergic disorders involving
mechanisms that fall between IgE-mediated food allergy
and cellular-mediated hypersensitivity disorders. They
selectively affect the gastrointestinal tract with eosinophil
rich inflammation in the absence of known causes for
eosinophilia[1]. The clinical presentation depends on the
gastrointestinal division affected and the wall layers infil-
trated. Eosinophils have been shown to be integral mem-
bers of the gastrointestinal mucosal immune system, but
their presence in deeper layers is almost always patho-
Endoscopic biopsy of ileum showing distinct eosinophilic infiltration (haematoxylin and eosin ×100)Figure 2
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against multicellular helminthic parasites. Many of the
secreted proteins are potent helminthotoxins. Other prod-
ucts affect smooth muscle contraction, vascular permea-
bility and the release of other mediators from mast cells
and basophiles[3].
Eosinophilic gastroenteritis is still a quite rare disease, but
EGIDs are currently being recognized more fre-
quently[5,6]. Patients with EGIDs present with a variety of
clinical problems, most commonly failure to thrive,
abdominal pain, irritability, gastric dysmotility, vomiting,
diarrhoea and dysphagia[7]. Thus the variety of non-spe-
cific common gastrointestinal symptoms und laboratory
findings explains why the correct diagnosis is completely
dependent on the microscopic examination of the biopsy
samples. The clinical presentation depends on the divi-
sion affected and the wall layers infiltrated. Patients with
primarily mucosal disease tend to present with non-spe-
cific gastrointestinal symptoms while those with serosal
disease can present with severe abdominal pain and
ascites[8].
Our patient suffered from recurring severe non-specific
abdominal pains for about five years, causing several hos-
pital stays and two laparoscopic interventions. Approxi-
mately one year before admission to our hospital the
patient developed ascites. Eosinophilic ascites is only
observed in 10 % of cases. It indicates the involvement of
the tunica serosa and is typical in women of childbearing
age[9]. Laparoscopy showed a swollen intestinal tract and
lymph nodes resembling the aspect of intestinal tubercu-
losis. Thus ascites was screened for mycobacteria. One pcr
screening turned out positive. Microscopy and repeated
cultures from ascites, sputum and biopsy of intestinal
lymph nodes remained negative for mycobacteria at all
times. Lacking another coherent differential diagnosis
anti mycobacterial treatment was started. Despite therapy
for six month ascites and abdominal complaints
remained nearly unchanged. On admission no signs of
active tuberculosis were found. Skin test, chest x-ray, dou-
ble pcr screening as well as cultures from sputum and
ascites were negative. These findings raise the question if
the tuberculosis has been treated successfully or the first
pcr result has been false positive. Regarding the persisting
symptoms the latter seems more probable. Furthermore
international guidelines do not accept the single use of
nucleic acid amplification technique to establish the diag-
nosis tuberculosis[10].
The patient now presented again with same complaints
which strongly suggested an eosinophilic gastrointestinal
disorder. Retrospectively eosinophilia was present already
at the last hospital stay which argues for EG then. Exclu-
sion of other causes of eosinophilia, summarized in
Klein's criteria[11] and histopathological confirmation of
eosinophilic infiltration of the GI tract supported our ini-
tial diagnosis.
The diagnosis hypereosinophilic syndrome (HES) should
always be considered in patients with EGIDs[12]. But here
was no evidence of extraintestinal organ manifestation
(e.g. cardiorespiratory system or skin) in our patient. Bone
marrow analysis showed no signs of myodysplasia. Mark-
ers like vitamin B 12 and serum mast cell tryptase were
normal[13]. The FIP1L1-PDGFRA fusion event, which is
found in about half of the HES patients, was not present.
It is generated by a chromosomal deletion and indicates
that these cases are hematopoetic malignancies[14].
Taken together HES seemed to be very unlikely.
EG is an uncommon disease and, as such, no prospective
treatment studies are available. In literature, case reports
and small case series have reported positive impact from a
variety of agents. Besides corticosteroids, mast cell stabi-
lizers, antihistamins, leukotriene antagonists, octreotide
as well as restriction diets and resection of stenosed intes-
tinal segments (reviewed in [1]). Based on this data, sys-
temic steroids still can be considered first choice therapy
in non obstructive disease. Unfortunately relapses are
common. These patients require long term low-dose pred-
nisone or immunosuppressive therapy, which is problem-
atic especially in young patients. Cysteinyl leukotrienes,
along with cytokines interleukin 3 and 5 and granulocyte
macrophage-colony stimulating factor seem to play a cru-
cial role in the recruitment of eosinophils into the tissue
causing damage. The leukotriene antagonist (LTRA) Mon-
telukast blocking the leukotriene receptor Cys-LT1 could
be the rationale to treat EG with this drug[15]. Anti-leuko-
triene drugs are considered generally safe and effective in
most patients. However there have been reports about the
association between LTRA and the development of Churg-
Strauss-Syndrome (CSS)[16]. So clinicians need to vigi-
lant of any development of CSS in any patient receiving
these agents. Up to now no side effects were noted in our
patient.
There has been one study with promising short term
results in children treated with Montelukast[17]. But only
two cases reporting successful control of symptoms in
eosinophilic gastroenteritis in adults[18]. Schwartz and
co-workers were first to report control of symptoms over
twenty months[19]. One more recent study found
improvement in peripheral blood but not in tissue eosi-
nophilia or symptoms in a severe, long-standing dis-
ease[20]. The presented case now shows successful long
term treatment with Montelukast over a period of two
years.Page 4 of 5
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Eosinophilic gastroenteritis is a rare disease, but should be
considered as differential diagnosis in cases of recurrent
abdominal pain. Failure to diagnose this disorder often
relates to reluctance to biopsy an apparently normal
intestinum. Montelukast therapy seems promising to be
an effective long term treatment in these patients, particu-
larly when they are steroid dependent. So far no side
effects were noted in our patient. Further randomized tri-
als are required to asses the full benefits of Montelukast
therapy in eosinophilic gastrointestinal disorders.
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